newsfilter
← Latest News
PR Newswire·

Liminal BioSciences Announces Discontinuation of Fezagepras Development

LAVAL, QC and CAMBRIDGE, England, July 21, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company") today announced that it has discontinued development of fezagepras.